Second-line and subsequent therapy for ovarian carcinoma
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology
Link
http://link.springer.com/content/pdf/10.1007/s11912-002-0077-0.pdf
Reference41 articles.
1. Thigpen JT: Chemotherapy for advanced ovarian cancer: overview of randomized trials. Semin Oncol 2000, 27:11–16.
2. Blackledge G, Lawton F, Redman C, et al.: Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 1989, 59:650–653.
3. Markman M, Hoskins W: Responses to salvage therapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol 1992, 10:513–514.
4. Rose PG, Fusco N, Fluellen L, et al.: Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 1998, 16:1494–1497. This seminal publication documents the role for retreatment of patients with previously effective chemotherapy who are more than 12 months from effective first-line therapy.
5. Berek JS, Bertelson K, du Bois A, et al.: Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 1999, 10(suppl 1):S87-S92.
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. The sequential use of endocrine treatment for advanced breast cancer: where are we?;Annals of Oncology;2012-06
2. Autologous white blood cell transfusion: Toward a younger immunity;Human Immunology;2007-10
3. Dihydrodiol dehydrogenase in drug resistance and sensitivity of human carcinomas;Cancer Chemotherapy and Pharmacology;2006-09-29
4. A Novel Assay to Assess Primary Human Cancer Infectibility by Replication-Selective Oncolytic Adenoviruses;Clinical Cancer Research;2005-01-01
5. Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter;Gynecologic Oncology;2004-03
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3